abstract |
A targeted therapeutic comprising a lysosomal targeting moiety that is a peptide comprising a lysosomal enzyme and containing at least one N-linked glycosylation site. The method for producing a targeted therapeutic can include a host cell that co-expresses a nucleotide acid encoding the targeted therapeutic and GNPT. A pharmaceutical composition comprising a targeted therapeutic and a method for its use for treating lysosomal storage diseases. In some embodiments, the peptide contains N-linked glycosylation. In some embodiments, the peptide contains an N-linked glycosylation containing an M6P group. |